[go: up one dir, main page]

AR044935A1 - Multiparticulados que contienen oxicodona - Google Patents

Multiparticulados que contienen oxicodona

Info

Publication number
AR044935A1
AR044935A1 ARP040102264A ARP040102264A AR044935A1 AR 044935 A1 AR044935 A1 AR 044935A1 AR P040102264 A ARP040102264 A AR P040102264A AR P040102264 A ARP040102264 A AR P040102264A AR 044935 A1 AR044935 A1 AR 044935A1
Authority
AR
Argentina
Prior art keywords
oxycodone
containing oxycodone
multiparticulates containing
multiparticulates
water
Prior art date
Application number
ARP040102264A
Other languages
English (en)
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33556051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR044935(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0315137A external-priority patent/GB0315137D0/en
Priority claimed from GB0403102A external-priority patent/GB0403102D0/en
Priority claimed from GB0413454A external-priority patent/GB0413454D0/en
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of AR044935A1 publication Critical patent/AR044935A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

Se pueden hacer multiparticulados de oxicodona por extrusión de una mezcla que contiene de manera apropiada (a) oxicodona, (b) copolímero de metacrilato de amonio insoluble en agua, (c) plastificante, (d) lubricante, y (e9 modificador de la permeabilidad ante el agua. Método para prepararlos, composición farmacéutica que los contienen y método para proveer alivio del dolor.
ARP040102264A 2003-06-27 2004-06-25 Multiparticulados que contienen oxicodona AR044935A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0315137A GB0315137D0 (en) 2003-06-27 2003-06-27 Multiparticulates
GB0403102A GB0403102D0 (en) 2004-02-12 2004-02-12 Multiparticulates
GB0413454A GB0413454D0 (en) 2004-06-16 2004-06-16 Multiparticulates

Publications (1)

Publication Number Publication Date
AR044935A1 true AR044935A1 (es) 2005-10-12

Family

ID=33556051

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102264A AR044935A1 (es) 2003-06-27 2004-06-25 Multiparticulados que contienen oxicodona

Country Status (25)

Country Link
EP (2) EP1889621B1 (es)
JP (2) JP5348841B2 (es)
KR (1) KR101116518B1 (es)
AR (1) AR044935A1 (es)
AT (1) ATE453394T1 (es)
AU (1) AU2004251481B2 (es)
BR (1) BRPI0411901B1 (es)
CA (1) CA2530385C (es)
CY (2) CY1109917T1 (es)
DE (1) DE602004024888D1 (es)
DK (2) DK1644002T3 (es)
EA (1) EA013424B1 (es)
ES (2) ES2337468T3 (es)
HR (2) HRP20100127T1 (es)
IL (1) IL172730A (es)
MX (1) MXPA05013799A (es)
MY (1) MY176831A (es)
NO (1) NO20060443L (es)
NZ (1) NZ544181A (es)
PE (1) PE20050286A1 (es)
PL (2) PL1644002T3 (es)
PT (2) PT1644002E (es)
SI (2) SI1889621T1 (es)
TW (1) TWI357815B (es)
WO (1) WO2005000310A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CA2314893C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
ATE493130T1 (de) 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
DE17154462T1 (de) 2002-04-05 2019-12-19 Euro-Celtique S.A. Matrix für nachhaltige, invariante und unabhängige freisetzung von wirkstoffverbindungen
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
GB2418854B (en) * 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
AP2274A (en) * 2005-01-28 2011-08-19 Euro Celtiques Sa Alcohol resistant dosage forms.
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070190142A1 (en) * 2006-01-21 2007-08-16 Abbott Gmbh & Co. Kg Dosage forms for the delivery of drugs of abuse and related methods
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
EP2144599B1 (en) * 2007-03-02 2010-08-04 Farnam Companies, Inc. Sustained release pellets comprising wax-like material
JP2010531807A (ja) 2007-05-25 2010-09-30 トルマー セラピューティクス， インコーポレイテッド リスペリドン化合物の徐放送達製剤
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
MY147827A (en) 2007-10-19 2013-01-31 Otsuka Pharma Co Ltd Pharmaceutical solid preparation
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
AU2009294308B2 (en) * 2008-09-18 2013-05-30 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(e-caprolactone)
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
ME03298B (me) 2009-03-10 2019-07-20 Euro Celtique Sa Farmaceutske kombinacije sa trenutnim oslobađanjem које obuhvataju oksikodon i nalokson
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
AU2010345740A1 (en) * 2010-02-11 2012-09-20 Harry Leider Methods of normalizing measured drug concentrations and testing for non-compliance with a drug treatment regimen
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
EA201590165A1 (ru) 2012-07-06 2015-08-31 Эгалет Лтд. Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
HUT69680A (en) * 1990-08-09 1995-09-28 Endocon Inc Implant and apparatus for delivering multiple drug and process for production of theese
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
JP4040084B2 (ja) * 1994-02-16 2008-01-30 アボツト・ラボラトリーズ 微粒子医薬調合物の調製プロセス
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
EP0857072B1 (en) * 1995-05-01 2003-01-15 Sam Yang Co., Ltd. Implantable bioresorbable membrane and method for the preparation thereof
SE505146C2 (sv) * 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
WO1997045091A2 (en) * 1996-05-31 1997-12-04 Euro-Celtique, S.A. Sustained release oxycodone formulations with no fed/fast effect
US6022554A (en) * 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
IT1304152B1 (it) * 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
FR2795326B1 (fr) * 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
KR101197919B1 (ko) * 1999-10-29 2012-11-29 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
AU776904B2 (en) * 2000-02-08 2004-09-23 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
FR2818552B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
KR20100120243A (ko) * 2002-05-07 2010-11-12 피시비다 유에스 인코포레이티드 약물 전달 장치를 형성하는 공정
CN1741792A (zh) * 2003-01-24 2006-03-01 控制递送系统有限公司 经眼部递送肾上腺素能剂的持续释放系统和方法
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates

Also Published As

Publication number Publication date
AU2004251481B2 (en) 2010-01-28
AU2004251481A1 (en) 2005-01-06
CA2530385A1 (en) 2005-01-06
ES2490598T3 (es) 2014-09-04
IL172730A (en) 2010-12-30
BRPI0411901A (pt) 2006-08-08
PL1889621T3 (pl) 2014-10-31
CY1115415T1 (el) 2017-01-04
PL1644002T3 (pl) 2010-05-31
CA2530385C (en) 2013-05-28
PT1644002E (pt) 2010-03-03
EP1644002A1 (en) 2006-04-12
IL172730A0 (en) 2006-04-10
JP2013209387A (ja) 2013-10-10
ATE453394T1 (de) 2010-01-15
EP1889621B1 (en) 2014-05-21
MY176831A (en) 2020-08-24
SI1644002T1 (sl) 2010-03-31
HRP20140635T1 (hr) 2014-09-26
ES2337468T3 (es) 2010-04-26
JP2007520429A (ja) 2007-07-26
NO20060443L (no) 2006-01-27
TWI357815B (en) 2012-02-11
CY1109917T1 (el) 2014-09-10
EA013424B1 (ru) 2010-04-30
EP1644002B1 (en) 2009-12-30
TW200510000A (en) 2005-03-16
JP5348841B2 (ja) 2013-11-20
EA200600111A1 (ru) 2006-06-30
KR20060026892A (ko) 2006-03-24
KR101116518B1 (ko) 2012-03-13
DK1889621T3 (da) 2014-08-11
PT1889621E (pt) 2014-08-27
SI1889621T1 (sl) 2014-09-30
MXPA05013799A (es) 2006-03-13
EP1889621A1 (en) 2008-02-20
DE602004024888D1 (de) 2010-02-11
NZ544181A (en) 2008-12-24
DK1644002T3 (da) 2010-04-19
HRP20100127T1 (hr) 2010-04-30
JP5960089B2 (ja) 2016-08-02
PE20050286A1 (es) 2005-06-13
NO333779B1 (es) 2013-09-16
BRPI0411901B1 (pt) 2019-04-02
WO2005000310A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
AR044935A1 (es) Multiparticulados que contienen oxicodona
ECSP003847A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
UY31497A1 (es) Nuevos compuestos para el tratamiento de trastornos del snc
ECSP088461A (es) Composiciones farmacéuticas que contienen buprenorfina
HN2003000094A (es) Indazoles subtituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.
HN2004000490A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
AR047540A1 (es) Particulados
AR109263A2 (es) Composición que comprende moxidectina
UY28348A1 (es) Compuestos novedosos
CR8428A (es) Agente endoparasiticidas para la administracion topica
PA8586201A1 (es) Nuevas formulaciones de liberacion prolongada inyectables
CO2024000890A2 (es) Compuestos de heteroarilo para tratar la enfermedad de huntington
HN2003000183A (es) Difenilazetidinonas sustituidas en anillo procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
AR031761A1 (es) Kit de repinotano
ES2170759T3 (es) Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos.
ATE347358T1 (de) Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
CY1104971T1 (el) Παρασκευασμα αποϊνιδοτιδιου και g-csf και η χρηση του για να κινητοποιει αιμοποιητικους προγονους
DK1220676T3 (da) Forebyggelse af colorektal cancer
AR043173A1 (es) Uso de dipiridamol en combinacion con acido acetilsalicilico y un antagonista de angiotensina ii para la prevencion de accidente cerebrovascular
DK1537132T3 (da) Salt af mortin-6-glucuronid
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
UY28390A1 (es) Multiparticulados

Legal Events

Date Code Title Description
FC Refusal